Clinical Trial Update: Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the mode of action of omalizumab in chronic idiopathic urticaria patients who do not respond to antihistamines; results have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Urticaria

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Idiopathic Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2014-11-03